Maintenance of Noninvasive Brain Stimulation for Preventing Relapse in Depression: A Systematic Review and Meta-Analysis

维持非侵入性脑刺激治疗以预防抑郁症复发:系统评价和荟萃分析

阅读:1

Abstract

BACKGROUND: Depression relapse rates remain high after acute treatment; this study evaluates the efficacy of maintenance noninvasive brain stimulation in preventing relapse and identifies optimal treatment parameters. METHODS: This meta-analysis was conducted following PRISMA guidelines. We conducted a systematic search of PubMed, Embase, Web of Science, Cochrane Library, and PsycINFO databases up to January 5, 2025. The primary outcome was relapse rate. RESULTS: A total of nine randomized controlled trials with 837 participants were included, six studies used electroconvulsive therapy (ECT) and three studies used repetitive transcranial magnetic stimulation (rTMS). Our findings indicate that ECT combined with pharmacotherapy or rTMS alone demonstrated superiority over pharmacotherapy alone in reducing the relapse of depression during 6, 9, 12-month maintenance treatment periods. Interestingly, ECT alone did not show significant results. In terms of stimulation parameters, the ECT combined with pharmacotherapy group mainly received right unilateral stimulation, while the ECT alone group had bitemporal stimulation. The stimulation frequency was similar between the two groups. In contrast, the rTMS-alone group had significantly higher stimulation frequencies than the ECT groups. We did not find any eligible studies on transcranial direct current stimulation, transcranial alternating current stimulation or magnetic seizure therapy, but they also showed potential in the maintenance treatment of depression, which warrants further investigation. CONCLUSIONS: ECT combined with pharmacotherapy, or rTMS alone, is more effective than pharmacotherapy alone in preventing relapse of depression during 6 to 12 months of maintenance treatment. Future research should prioritize identifying the optimal treatment regimen and exploring the potential of combination therapies. THE PROSPERO REGISTRATION: CRD42023490546, https://www.crd.york.ac.uk/PROSPERO/view/CRD42023490546.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。